Loading news...
Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets approval from the Food and Drug Administration.
Novo Nordisk (NVO) is moving decisively to reinforce its manufacturing base, announcing a â¬432 million ($507 million) investment to upgrade and retrofit its A
Eli Lilly's ongoing innovations could set the business up for a long time. The company also has a strong dividend program.
Eli Lilly wins CHMP backing to expand Olumiant use in adolescents with severe alopecia areata, with the EU approval decision expected shortly.
Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland. The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Davis R M Inc. increased its position in shares of Eli Lilly and Company (NYSE: LLY) by 9.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,372 shares of the company's stock after buying an additional 5,210 shares during the quarter. Davis
Bahl and Gaynor Inc. reduced its holdings in Eli Lilly and Company (NYSE: LLY) by 3.3% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 803,980 shares of the company's stock after selling 27,509 shares during the quarter. Eli Lilly and Company makes
Defiance Daily Target 2X Long LLY ETF (NYSEARCA:LLYX - Get Free Report) saw a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 90,658 shares, a growth of 92.5% from the January 29th total of 47,102 shares. Currently, 5.3% of the company's shares are short
Weekly Market HighlightsMarket breadth was slightly positive with 4,817 advancers versus 4,692 decliners, but performance was highly skewed as the mean weekly
American Century Companies Inc. lifted its holdings in Eli Lilly and Company (NYSE: LLY) by 6.6% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,961,645 shares of the company's stock after buying an additional 120,905 shares during the quarter. Eli
Novo Nordisk (NVO) has now surrendered the last of the gains that followed the 2021 US approval of Wegovy, marking a decisive turn in what had been one of Europ
WSJ's David Wainer breaks down why Novo Nordisk struggled and Eli Lilly prospered in the weight loss drug market. #
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is the first and largest of its kind specifically designed to evaluate children and adolescents with severe AA, a disease that has devastating social and emotional impact Lilly has also submitted Olumiant in the U.S. for approval to treat severe AA in adolescents, with a decision expected in the second half of 2026 INDIANAPOLIS, Feb. 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents (ages 12 to
Stock News Nvidia posts record quarter, upbeat outlook: Nvidia (NVDA) reported Q4 revenue of $68.13B with data center sales at $62.3B (91% of total) and guided
Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more detailed picture of the side effects.
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026 INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1 without food or water restrictions, compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin.